Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide (SMS 201-995).

摘要: The new long-acting somatostatin analogue octreotide (SMS 201-995) was investigated for its influence on secretagogue-stimulated human exocrine pancreatic secretion. Eighteen healthy volunteers participated in the study. During duodenal intubation with a background stimulation of either secretin 1 U.kg/h or + ceruletide, 120 ng.kg/h, infused at doses 5, 20 and 80 micrograms/h placebo-controlled randomized double-blind crossover trial. Duodenal juice samples were collected 10-min intervals, amylase, trypsin, chymotrypsin, bicarbonate measured individual fractions. stimulation, amylase inhibited between 41 59%, trypsin 28 72%, chymotrypsin 55 70%, 0 31% octreotide. ceruletide significantly by 84%, 78%, 81%, 76%, 55%, 52%, 77%, 60%, 25%, 11%, 19% 20, octreotide, respectively (all decreases P less than 0.05). confirmed to be potent inhibitor stimulated near maximal inhibitory potency achieved dose only 5 micrograms/h. This finding may value planning therapeutic studies